share_log

榮昌生物：海外監管公告 - 榮昌生物製藥（煙台）股份有限公司2024年度“提質增效重回報”行動方案

REMEGEN: An announcement has just been published by the issuer in the Chinese section of this website, a corresponding version of which may or may not be published in this section

香港交易所 ·  Mar 27 19:15
Summary by Moomoo AI
荣昌生物宣布了2024年度“提质增效重回报”行动方案，旨在提升公司核心竞争力、优化团队结构推动商业化、实施国际化发展战略、加强募投项目管理以提升科技创新能力、优化财务管理提高经营效率、完善公司治理、提升信息披露质量、加强投资者交流、持续完善投资者回报机制、强化管理层与股东的利益共担共享约束。公司将聚焦经营主业，加大研发投入，优化营销队伍结构，推动药物全球多中心临床试验及注册过程，积极寻求跨国药企合作。此外，公司将继续推进募投项目，包括生物新药产业化项目、抗肿瘤抗体新药研发项目等，以增强盈利能力。公司还将优化财务管理，提高盈利质量和资金效率，加强人力资源管理。荣昌生物将持续评估行动方案的执行情况，专注主业，通过良好的经营管理、规范的公司治理和积极的投资者回报，保护投资者利益，维护公司市场形象，促进资本市场平稳健康发展。
荣昌生物宣布了2024年度“提质增效重回报”行动方案，旨在提升公司核心竞争力、优化团队结构推动商业化、实施国际化发展战略、加强募投项目管理以提升科技创新能力、优化财务管理提高经营效率、完善公司治理、提升信息披露质量、加强投资者交流、持续完善投资者回报机制、强化管理层与股东的利益共担共享约束。公司将聚焦经营主业，加大研发投入，优化营销队伍结构，推动药物全球多中心临床试验及注册过程，积极寻求跨国药企合作。此外，公司将继续推进募投项目，包括生物新药产业化项目、抗肿瘤抗体新药研发项目等，以增强盈利能力。公司还将优化财务管理，提高盈利质量和资金效率，加强人力资源管理。荣昌生物将持续评估行动方案的执行情况，专注主业，通过良好的经营管理、规范的公司治理和积极的投资者回报，保护投资者利益，维护公司市场形象，促进资本市场平稳健康发展。
Rong Cheong Bio announced its 2024 “Enhancing the Effectiveness Review” Action Plan to enhance the company's core competitiveness, optimize team structure to promote commercialization, implement internationalization development strategy, strengthen investment project management to enhance technology innovation capacity, optimize financial management, improve operational efficiency, and improve corporate governance Improve the quality of information disclosure, strengthen investor communication, continue to improve investor feedback mechanisms, strengthen the constraints on shared interests of management and shareholders. The company will focus on operations, increase R&D investments, optimize marketing team structure, drive multi-center clinical trials and registration of drugs globally, and seek cooperation from multinational pharmaceutical companies. In addition, the Company will continue to pursue investment projects, including biopharmaceuticals, new anti-tumor antibody R...Show More
Rong Cheong Bio announced its 2024 “Enhancing the Effectiveness Review” Action Plan to enhance the company's core competitiveness, optimize team structure to promote commercialization, implement internationalization development strategy, strengthen investment project management to enhance technology innovation capacity, optimize financial management, improve operational efficiency, and improve corporate governance Improve the quality of information disclosure, strengthen investor communication, continue to improve investor feedback mechanisms, strengthen the constraints on shared interests of management and shareholders. The company will focus on operations, increase R&D investments, optimize marketing team structure, drive multi-center clinical trials and registration of drugs globally, and seek cooperation from multinational pharmaceutical companies. In addition, the Company will continue to pursue investment projects, including biopharmaceuticals, new anti-tumor antibody R&D projects, etc., to increase profitability. The company will also optimize financial management, improve profit quality and capital efficiency, and strengthen human resource management. RONG CHANG BIO WILL CONTINUE TO EVALUATE THE EXECUTION OF THE ACTION PLAN, FOCUS ON THE MAIN BUSINESS, PROMOTE THE STABLE AND HEALTHY DEVELOPMENT OF THE CAPITAL MARKET THROUGH GOOD OPERATIONAL MANAGEMENT, REGULATORY CORPORATE GOVERNANCE AND COMPREHENSIVE INVESTOR FEEDBACK.

This announcement is a separate document:

Doc 1     View Translation

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more